PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
Top Cited Papers
Open Access
- 23 February 2017
- journal article
- Published by American Society of Hematology in Blood
- Vol. 129 (8), 1039-1041
- https://doi.org/10.1182/blood-2016-09-738245
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Faculty Opinions recommendation of Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.Published by H1 Connect ,2016
- Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ LymphomasBlood, 2015
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaScience Translational Medicine, 2015
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T CellsClinical Cancer Research, 2013
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaThe New England Journal of Medicine, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009